Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-FR Version v5-EN
Language French English
Date Updated 2023-06-15 2022-10-31
Drug Identification Number 02469901 02469901
Brand name ADMELOG ADMELOG
Common or Proper name ADMELOG VIAL ADMELOG VIAL
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients INSULIN LISPRO INSULIN LISPRO
Strength(s) 100UNIT 100UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size 10 mL vial, 1 vial/box 10 mL vial, 1 vial/box
ATC code A10AB A10AB
ATC description INSULINS AND ANALOGUES INSULINS AND ANALOGUES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2022-10-31 2022-10-31
Estimated end date 2023-07-31 2023-01-16
Actual end date 2023-06-14
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Supply delay. Shortage can be intermittent as Sanofi may receive partial shipments, until full resolution expected on “Estimated end date”. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Supply delay. Shortage can be intermittent as Sanofi may receive partial shipments, until full resolution expected on “Estimated end date”. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date.
Health Canada comments